Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination Therapy with Interferon-Alpha2a and Ruxolitinib in Polycythemia Vera
2018-004150-13Phase 2Active
- Sponsor
- Zealand University Hospital
- Start
- Oct 2018
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of ruxolitinib and peginterferon alfa-2a in polycythemia vera (PV), sponsored by Zealand University Hospital. Primary endpoint: Primary safety profile. Started Oct 2018; status: active.
02
Drugs
ruxolitinibpeginterferon alfa-2a
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on 2018-004150-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004150-13.